2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro

doi:10.1055/s-0035-1564814

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2015; 41(07): 673-679
DOI: 10.1055/s-0035-1564814

Editorial

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

References
1 Favaloro EJ. Editorial. Welcome to a special issue of Seminars in Thrombosis & Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008; 34: 693-696
2 Favaloro EJ. Preface. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (8) 703-707
3 Favaloro EJ. Editorial. Welcome to the first issue of Seminars in Thrombosis & Hemostasis for 2009. Semin Thromb Hemost 2009; 35: 1-2
4 Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen award for most popular article. Semin Thromb Hemost 2009; 35: 587-590
5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen young investigator award winners. Semin Thromb Hemost 2010; 36: 469-470
6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008-2009. Semin Thromb Hemost 2010; 36 (7) 685-692
7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2011; 37 (5) 431-439
8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2012; 38 (5) 425-432
9 Favaloro EJ. 2013 Eberhard F. Mammen award announcements. Semin Thromb Hemost 2013; 39 (6) 567-574
10 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I - most popular articles. Semin Thromb Hemost 2014; 40 (4) 407-412
11 Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II-Young Investigator Awards. Semin Thromb Hemost 2014; 40 (7) 718-723
12 Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013; 39 (4) 452-458
13 George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013; 39 (2) 153-160
14 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39 (5) 559-566
15 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (6) 585-595
16 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
17 Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013; 39 (2) 191-201
18 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
19 Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. Semin Thromb Hemost 2013; 39 (5) 469-476
20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010; 36 (8) 807-818
21 McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 2013; 39 (1) 101-111
22 Barco S, Nijkeuter M, Middeldorp S. Pregnancy and venous thromboembolism. Semin Thromb Hemost 2013; 39 (5) 549-558
23 Franchini M, Coppola A, Rocino A , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (7) 752-766
24 Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 2013; 39 (2) 127-140
25 Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism in neonates and children. Semin Thromb Hemost 2012; 38 (7) 683-690
26 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003; 29 (5) 435-450
27 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 632-641
28 Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 2013; 39 (1) 48-58
29 Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 2013; 39 (4) 356-364
30 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012; 38 (5) 454-462
31 Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39 (6) 621-631
32 Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28 (3) 247-256
33 Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013; 39 (7) 840-846
34 Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost 2011; 37 (3) 237-251
35 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (5) 579-589
36 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (5) 483-496
37 Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost 2010; 36 (1) 59-70
38 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31 (4) 381-392
39 Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36 (8) 888-906
40 Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009; 35 (4) 400-406
41 Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013; 39 (2) 147-152
42 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37 (3) 267-274
43 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39 (2) 117-126
44 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012; 38 (7) 673-682
45 Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011; 37 (3) 280-297
46 Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014; 40 (1) 60-65
47 Italiano Jr JE. Unraveling mechanisms that control platelet production. Semin Thromb Hemost 2013; 39 (1) 15-24
48 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
49 Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014; 40 (1) 106-114
50 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (8) 709-733
51 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012; 38 (1) 47-54
52 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (2) 189-203
53 Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. Semin Thromb Hemost 2013; 39 (3) 291-305
54 Kenet G, Aronis S, Berkun Y , et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011; 37 (7) 802-809
55 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 2014; 40 (1) 121-128
56 Raskob GE, Angchaisuksiri P, Blanco AN , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost 2014; 40 (7) 724-735
57 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40 (3) 277-283
58 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34 (8) 772-778
59 Fareed J, Hoppensteadt DA, Fareed D , et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008; 34 (1) 58-73
60 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40 (2) 163-171
61 Harenberg J, Kraemer S, Du S , et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014; 40 (1) 129-134